Intracellular Ca2+ concentration and the antidiuretic hormone-induced increase in water permeability: effects of ionophore A23187 and quinidine.
The hydroosmotic responses induced by oxytocin and 8-bromo-cyclic AMP, in frog and toad urinary bladders, were recorded minute by minute. 3HHO and 45Ca unidirectional fluxes as well as prostaglandin B2 liberation were also measured. It was observed that: (1) Addition of the calcium ionophore A23187 or quinidine to the serosal bath inhibited the response to oxytocin, but not to 8-bromo-cyclic AMP, while increasing prostaglandin E1 liberation into the serosal but not into the mucosal bath. (2) Addition of A23187 to the mucosal bath induced a transient and temperature-dependent inhibition of the response elicited by 8-bromo-cyclic AMP. The time-course of this reduction in water permeability and its sensitivity to medium temperature were similar to those observed after the withdrawal of agonist, but clearly different of those observed after intracellular acidification. (3) The hydroosmotic response was also transitorily inhibited when the Ca2+ concentration was step-changed in the mucosal bath. (4) When added to the mucosal or to the serosal baths, the ionophore increased either the apical or the laterobasal Ca2+ permeabilities. It is concluded that manipulation of intracellular Ca2+ interferes with the hydroosmotic response at two different levels. (1) A first target point located 'pre-cyclic-AMP production'. This effect would be mediated by prostaglandin liberation. (2) A second target point located after cyclic AMP production and before the 'temperature-dependent rate-limiting step'. This effect is probably related to the mechanism controlling the insertion and removal of water channels.
Parisi
M
M
Departamento de Fisiologia, Facultad de Medicina, Universidad de Buenos Aires, Argentina.
Ibarra
C
C
Porta
M
M
D015124:8-Bromo Cyclic Adenosine Monophosphate / Q000494:pharmacology; D000818:Animals; D001692:Biological Transport / Q000187:drug effects; D002022:Bufo arenarum; D000001:Calcimycin / Q000494:pharmacology*; D002118:Calcium / Q000378:metabolism*; D002463:Cell Membrane Permeability / Q000187:drug effects*; D000242:Cyclic AMP / Q000378:metabolism; D015232:Dinoprostone; D006863:Hydrogen-Ion Concentration; D009995:Osmosis / Q000187:drug effects; D010121:Oxytocin / Q000037:antagonists & inhibitors / Q000494:pharmacology; D011458:Prostaglandins E / Q000378:metabolism; D011802:Quinidine / Q000494:pharmacology*; D011893:Rana esculenta; D013696:Temperature; D001743:Urinary Bladder / Q000378:metabolism; D014667:Vasopressins / Q000494:pharmacology*; D014867:Water / Q000378:metabolism*
D011458:Prostaglandins E; D014867:Water; D014667:Vasopressins; D015124:8-Bromo Cyclic Adenosine Monophosphate; D000001:Calcimycin; D010121:Oxytocin; D000242:Cyclic AMP; D011802:Quinidine; D015232:Dinoprostone; D002118:Calcium